

S5 Table. Clinical, surgical, pathological characteristics, and oncologic outcomes of the development and test sets

Variable	Development set (n=101)	Test set (n=44)	p-value
Age (yr)			
At the time of diagnosis, mean±SD	60.9±8.6	60.1±9.2	0.626
Sex			
Female	44 (43.6)	21 (47.7)	0.644
Male	57 (56.4)	23 (52.3)	
Serum CA19-9 at baseline (U/mL)			
≤ 37	29 (28.7)	21 (47.7)	0.027
> 37	72 (71.3)	23 (52.3)	
Serum CA19-9 preop. (U/mL)			
≤ 37	60 (59.4)	32 (72.7)	0.127
> 37	41 (40.6)	12 (27.3)	
Serum CA19-9 response			
Initially not elevated	33 (32.7)	12 (27.3)	0.076
Normalized	29 (28.7)	21 (47.7)	
Not normalized	39 (38.6)	11 (25.0)	
Serum CEA baseline (ng/mL)			
≤ 5	76 (75.2)	33 (75.0)	0.975
> 5	25 (24.8)	11 (25.0)	
Serum CEA preop. (ng/mL)			
≤ 5	89 (88.1)	35 (79.5)	0.179
> 5	12 (11.9)	9 (20.5)	
Serum total bilirubin baseline (mg/dL)			
≤ 1.5	49 (48.5)	33 (75.0)	0.003
> 1.5	52 (51.5)	11 (25.0)	
Serum total bilirubin preop. (mg/dL)			
≤ 1.5	96 (95.0)	41 (93.2)	0.652
> 1.5	5 (5.0)	3 (6.8)	
Neoadjuvant treatment			
With radiation	88 (87.1)	10 (22.7)	< 0.001
Without radiation	13 (12.9)	34 (77.3)	
Pancreatectomy type			
Distal pancreatectomy	19 (18.8)	11 (25.0)	0.086
Whipple's operation or PPPD	81 (80.2)	30 (68.2)	
Total pancreatectomy	1 (1.0)	3 (6.8)	
Resection margin status			
R0	78 (77.2)	20 (45.5)	< 0.001
R1	23 (22.8)	24 (54.5)	
Tumor differentiation grade			
Well	9 (8.9)	8 (18.2)	0.028
Moderate, moderate to poor	61 (60.4)	27 (61.4)	
Poor	9 (8.9)	7 (15.9)	
N/A	22 (21.8)	2 (4.5)	
ypT stage			
0	10 (9.9)	4 (9.1)	0.419
1	43 (42.6)	20 (45.5)	
2	35 (34.7)	18 (40.9)	
3	5 (5.0)	2 (4.5)	
4	0	0	
N/A	8 (7.9)	0	
ypN stage			

0	73 (72.3)	26 (59.1)	0.277
1	24 (23.8)	16 (36.4)	
2	4 (4.0)	2 (4.5)	
ypM stage			
0	92 (91.1)	41 (93.2)	0.675
1	9 (8.9)	3 (6.8)	
ypTNM stage			
0	10 (9.9)	4 (9.1)	0.663
IA	34 (33.7)	16 (36.4)	
IB	19 (18.8)	5 (11.4)	
IIA	2 (2.0)	1 (2.3)	
IIB	20 (19.8)	14 (31.8)	
III	3 (3.0)	1 (2.3)	
IV	9 (8.9)	3 (6.8)	
N/A	4 (4.0)	0	
Surgery-proved metastatic site			
No surgery-proved metastasis	92 (91.1)	41 (93.2)	0.870
Para-aortic lymph node	5 (5.0)	2 (4.5)	
Liver	4 (4.0)	1 (2.3)	
Interval from baseline CT to surgery (mo), median (IQR)	4.0 (3.4-6.2)	6.4 (4.6-9.4)	< 0.001
Adjuvant chemotherapy			
No	26 (25.7)	6 (13.6)	0.095
Yes	75 (74.3)	37 (84.1)	
N/A	0	1 (2.3)	
Survival status			
Alive	25 (24.8)	34 (77.3)	< 0.001
Died	76 (75.2)	10 (22.7)	
Overall survival since baseline CT (mo), median (95% confidence interval)	33.3 (25.5-44.9)	N/A ^{a)}	0.100
Recurrence status			
Recurrence-free	26 (25.7)	25 (56.8)	< 0.001
Recurred	75 (74.3)	19 (43.2)	
Recurrence-free survival (mo)	12.0 (9.7-19.0)	11.6 (9.5-13.2)	0.563

Values are presented as number (%) unless otherwise indicated. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CT, computed tomography; IQR, interquartile range; N/A, not available; PPPD, pylorus-preserving pancreaticoduodenectomy; preop., preoperative. ^{a)}More than 50% of the subjects were alive at the end of the study.